Clinical Trial Update: Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy [NA]

View source ↗

Summary

This clinical trial update describes a study evaluating biomarkers that predict 6-month survival for glioblastoma patients at first relapse after radiochemother…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Glioblastoma, Radiotherapy | NA | Status: RECRUITING